Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Prospective Outcomes of Second Line Therapy in Acute Gvhd: Six Month Freedom from Treatment Failure and Day 28 Response in a Multicentre Study

Rohini Radia, MD FRCPath, Arun Alfred, Matthew P. Collin, MD PhD, Maria H Gilleece, MD FRCPath, MB, BSc, FRCP, James E Griffin, BSc (Hons), MBChB (Hons), PhD, Ann E. Hunter, MBBS, FRCP, FRCPath, Hannah Hunter, MB, FRCPath, MRCP, Harpreet Kaur, Nandita Khera, MD, Kavita Raj, MD PhD, Emma Das-Gupta, DM, FRCPath, MRCP, Fiona Louise Dignan, MD, Madan Jagasia, MD MS

Blood (2018) 132 (Supplement 1): 3408.

https://doi.org/10.1182/blood-2018-99-115376

Published: 2018

Journal Articles

Therapy-Related Myeloid Neoplasms with Balanced Chromosome Rearrangements Frequently Arise from Pre-Existing Clonal Haematopoiesis

Richard Dillon, MA, PhD MRCP, FRCPath, Jelena Jovanovic, PhD, Nicola Potter, PhD, Nicola Foot, MSc, Matthew J Ahearne, MD MBBS, Sandrine Jayne, PhD, Michael Dennis, MD MRCP, FRCPath, Ann E. Hunter, MBBS, FRCP, FRCPath, Martin J.S. Dyer, Paresh Vyas, Lynn Quek, FRCPath, DPhil, MBBS, Nigel H. Russell, Robert K. Hills, MA, DPhil, MSc, Ellen Solomon, PhD, David Grimwade, PhD MRCP, MRCPath

Blood (2018) 132 (Supplement 1): 2570.

https://doi.org/10.1182/blood-2018-99-114233

Published: 2018

Journal Articles

A Randomised Comparison of the Sequential Addition of the FLT3 Inhibitor Lestaurtinib (CEP701) to Standard First Line Chemotherapy for FLT3-Mutated Acute Myeloid Leukemia: The UK Experience

Steven Knapper, DM, Robert K Hills, MA MSc DPhil, James D Cavenagh, MD, Lars Kjeldsen, MDPhD, Ann E. Hunter, MBBS, Richard E Clark, MBBS MD, Michael Dennis, MD, Donald Milligan, MD, Mark J Levis, MDPhD, Nigel Russell, Alan K. Burnett, MD

Blood (2014) 124 (21): 3736.

https://doi.org/10.1182/blood.V124.21.3736.3736

Published: 2014

Journal Articles

The ATRA Question In AML: Lack Of Benefit Overall Or In Any Molecular Subgroup In The NCRI AML16 Trial

Alan K. Burnett, MD, Robert K. Hills, MA, MSc, DPhil, Lone S. Friis, MD, PhD, Lars Kjeldsen, MD, PhD, Donald Milligan, MD, FRCP, FRCPath, Ann E. Hunter, MBBS, FRCP, FRCPath, Michelle Lazenby, Amanda F Gilkes, MSc, David Bowen, MD, PhD, Nigel Russell, MD

Blood (2013) 122 (21): 493.

https://doi.org/10.1182/blood.V122.21.493.493

Published: 2013

Journal Articles

AC220 (Quizartinib) Can Be Safely Combined With Conventional Chemotherapy In Older Patients With Newly Diagnosed Acute Myeloid Leukaemia: Experience From The AML18 Pilot Trial

Alan K. Burnett, MD, David Bowen, MD, PhD, Nigel Russell, MD, Steven Knapper, MD, Donald Milligan, MD, FRCP, FRCPath, Ann E. Hunter, MBBS, FRCP, FRCPath, Asim Khwaja, FRCPath, Richard E. Clark, MBBS, MD, FRCP, FRCPath, Dominic Culligan, Helen Clark, Robert K. Hills, MA, MSc, DPhil

Blood (2013) 122 (21): 622.

https://doi.org/10.1182/blood.V122.21.622.622

Published: 2013

Journal Articles

Reasons For Survival Improvement In Core Binding Factor AML: A 25 Year Analysis Of The UK MRC/NCRI AML Trials

Alan K. Burnett, MD, Robert K. Hills, MA, MSc, DPhil, Nigel Russell, MD, Donald Milligan, MD, FRCP, FRCPath, Ann E. Hunter, MBBS, FRCP, FRCPath, Richard E. Clark, MBBS, MD, FRCP, FRCPath, David Bowen, MD, PhD, Mary Frances McMullin, MD

Blood (2013) 122 (21): 358.

https://doi.org/10.1182/blood.V122.21.358.358

Published: 2013

Journal Articles

Paternity Wishes in Young Long-Term Survivors After Allogeneic Hematopoietic Stem Cell Transplantation. A Study of the Late Effects Working Party of the EBMT

Alicia Rovo, MD, Mahmoud Aljurf, M.D., Sandra Chiodi, MD, Simonetta Spinelli, MD, Nina Salooja, MD, Gülsan Sucak, MD, Ann E. Hunter, MBBS, FRCP, FRCPath, Tan Swee Kim, MD, Gérard Socié, Maria Teresa van Lint, Jakob R. Passweg, MD, Mutlu Arat, MD, Manuela Badoglio, André Tichelli, MD

Blood (2011) 118 (21): 2002.

https://doi.org/10.1182/blood.V118.21.2002.2002

Published: 2011

Journal Articles

The Addition of Gemtuzumab Ozogamicin to Intensive Chemotherapy in Older Patients with AML Produces a Significant Improvement in Overall Survival: Results of the UK NCRI AML16 Randomized Trial

Alan K Burnett, MD, Robert K Hills, MA, MSc, DPhil, Ann E. Hunter, MBBS, FRCP, FRCPath, Donald Milligan, MD, MBChB, William J. Kell, MD, MB, Keith Wheatley, John L Yin, MD, Sahra Ali, FRCPath, FRCP, BM, MRCP, MRCPath, Lars Kjeldsen, MD, PhD, David Bowen, Nigel H. Russell, MD

Blood (2011) 118 (21): 582.

https://doi.org/10.1182/blood.V118.21.582.582

Published: 2011

Journal Articles

Attempts to Optimise Induction and Consolidation Chemotherapy in Patients with Acute Myeloid Leukaemia: Results of the MRC AML15 Trial.

Alan K Burnett, Robert K Hills, Donald Milligan, MD, MBChB, Ann E. Hunter, MBBS, FRCP, FRCPath, Anthony H. Goldstone, FRCP, FRCPath, Archie Prentice, MBChB, FRCP, FRCPath, Brenda ES Gibson, Lars Kjeldsen, John AL Yin, Keith Wheatley, DPhil, Nigel H. Russell, MD

Blood (2009) 114 (22): 484.

https://doi.org/10.1182/blood.V114.22.484.484

Published: 2009

Journal Articles

Low Dose Ara-C Versus Low Dose Ara-C and Arsenic Trioxide: the UK NCRI AML16 “Pick a Winner” Comparison.

Nigel H. Russell, MD, Robert K Hills, Ann E. Hunter, MBBS, FRCP, FRCPath, Donald Milligan, MD, MBChB, William J. Kell, MD, MB, Keith Wheatley, DPhil, Mary Frances McMullin, John AL Yin, David T. Bowen, MD, A. Burnett, MD, FRCP

Blood (2009) 114 (22): 486.

https://doi.org/10.1182/blood.V114.22.486.486

Published: 2009

Journal Articles

The Role of In Vivo T-Cell Depletion On Reduced Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation From HLA-Identical Siblings in Patients with Follicular Lymphoma: An European Blood and Marrow Transplantation Study.

Julio Delgado, MD, PhD, Carme Canals, MD, Michel Attal, MD, Kirsty Thomson, MD, Antonio Campos, MD, Rodrigo Martino, MD, Timothy James Littlewood, MD, FRCP, Graham H Jackson, MD, Noel-Jean Milpied, MD, Johann Maertens, MD, Ann E. Hunter, MBBS, FRCP, FRCPath, Jeroen JWM Janssen, MD, Silvia Montoto, MD, Anna Sureda, MD, PhD

Blood (2009) 114 (22): 3375.

https://doi.org/10.1182/blood.V114.22.3375.3375

Published: 2009

NARROW

Prospective Outcomes of Second Line Therapy in Acute Gvhd: Six Month Freedom from Treatment Failure and Day 28 Response in a Multicentre Study

Therapy-Related Myeloid Neoplasms with Balanced Chromosome Rearrangements Frequently Arise from Pre-Existing Clonal Haematopoiesis

A Randomised Comparison of the Sequential Addition of the FLT3 Inhibitor Lestaurtinib (CEP701) to Standard First Line Chemotherapy for FLT3-Mutated Acute Myeloid Leukemia: The UK Experience

The ATRA Question In AML: Lack Of Benefit Overall Or In Any Molecular Subgroup In The NCRI AML16 Trial

AC220 (Quizartinib) Can Be Safely Combined With Conventional Chemotherapy In Older Patients With Newly Diagnosed Acute Myeloid Leukaemia: Experience From The AML18 Pilot Trial

Reasons For Survival Improvement In Core Binding Factor AML: A 25 Year Analysis Of The UK MRC/NCRI AML Trials

Paternity Wishes in Young Long-Term Survivors After Allogeneic Hematopoietic Stem Cell Transplantation. A Study of the Late Effects Working Party of the EBMT

The Addition of Gemtuzumab Ozogamicin to Intensive Chemotherapy in Older Patients with AML Produces a Significant Improvement in Overall Survival: Results of the UK NCRI AML16 Randomized Trial

Attempts to Optimise Induction and Consolidation Chemotherapy in Patients with Acute Myeloid Leukaemia: Results of the MRC AML15 Trial.

Low Dose Ara-C Versus Low Dose Ara-C and Arsenic Trioxide: the UK NCRI AML16 “Pick a Winner” Comparison.

The Role of In Vivo T-Cell Depletion On Reduced Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation From HLA-Identical Siblings in Patients with Follicular Lymphoma: An European Blood and Marrow Transplantation Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only